← Back to Clinical Trials
Recruiting NCT06874231

Brain Connectivity Marker for Alzheimer's Disease

Trial Parameters

Condition Alzheimer Disease
Sponsor Karolinska Institutet
Study Type OBSERVATIONAL
Phase N/A
Enrollment 120
Sex ALL
Min Age 40 Years
Max Age 85 Years
Start Date 2023-04-01
Completion 2027-07-31
Interventions
Neuroimaging

Brief Summary

The main purpose of this project is to establish whether changes in brain connectivity can be used to predict the development of Alzheimer's disease (AD).

Eligibility Criteria

Inclusion Criteria: 1. Inclusion criteria for subjects with subjective cognitive complaints: * MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 26 and 30. * Absence of cognitive impairment. * Memory problems reported by the participant/family member. * Do not fulfill criteria for mild cognitive impairment or dementia. * Must speak and understand Swedish. 2. Inclusion criteria for patients with mild cognitive impairment: * MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 24 and 30. * Impaired memory function. * Do not fulfill criteria for dementia. * Must speak and understand Swedish. * Must have abnormal cerebrospinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease. 3. Specific inclusion criteria for patients with Alzheimer's disease: * MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 18 and 28. * Impaired memory function in addition to impaired executive abilities,

Related Trials